Anti-infective hydroxy-phenyl-benzoates and methods of use
View Patent ↗The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus , for example, Staphylococcus aureus . The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically co-administering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analog and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.
1. A method for preventing or treating an infection caused by a microorganism, said method comprising systemically administering to a subject in need thereof a therapeutically effective amount of a salicylic acid (SAL) analogue, wherein the SAL analogue is a hydroxyl-phenyl-benzoate.
2. The method of claim 1 , wherein said microorganism is a strain that is resistant to at least one antibiotic.
3. The method of claim 1 , wherein the SAL analogue is Diflunisal (DIF).
4. The method of claim 1 , further comprising administering to the subject at least one additional antimicrobial agent.
5. The method of claim 4 , where said SAL analogue and said at least one additional antimicrobial agent are co-administered individually.
6. The method of claim 4 , where said SAL analogue and said at least one additional antimicrobial agent are co-administered collectively.
7. The method of claim 4 , wherein said at least one additional antimicrobial agent is an antibacterial agent.
8. The method of claim 7 , wherein said antibacterial agent is selected from the group consisting of penicillins, cephems, sulfonamides, aminoglycosides, chloramphenicol, tetracyclines, macrolides, lincosamindes, streptogramins, glycopeptides, rifamycins, nitroimidazoles, quinolones, dihydrofolate reductase inhibitors, oxazolidinones, lipopeptides, carbapenems, cephalosporins, monobactams, and dihydrofolate reductase inhibitors.
9. The method of claim 4 , wherein said at least one additional antimicrobial agent is an antifungal agent.
10. The method of claim 9 , wherein said antifungal agent is selected from the group consisting of polyenes, azole drugs, allylamine drugs, morpholine drugs, and antimetabolite antifungal drugs.